Inhibrx Biosciences (INBX) Cash & Equivalents (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Cash & Equivalents data on file, last reported at $124.2 million in Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $124.2 million, down 18.6% year-over-year; the trailing twelve-month figure through Dec 2025 was $124.2 million (down 18.6% YoY), and the FY2025 annual result was $124.2 million, down 18.6% from the prior year.
• Cash & Equivalents declined to $124.2 million in Q4 2025 per INBX's latest filing, from $153.1 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $277.9 million in Q4 2023 and troughed at $124.2 million in Q4 2025.
• A 3-year average of $191.8 million and a median of $191.4 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents tumbled 45.09% in 2024, then declined 17.78% in 2025.
• A 3-year view of Cash & Equivalents shows it stood at $277.9 million in 2023, then tumbled by 45.09% to $152.6 million in 2024, then slipped by 18.6% to $124.2 million in 2025.
• Business Quant data shows INBX's Cash & Equivalents at $124.2 million in Q4 2025, $153.1 million in Q3 2025, and $186.6 million in Q2 2025.